Stoke Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ian F. Smith
- Full Time Employees
- 170
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 45 Wiggins Avenue Bedford MA United States of America 01730
- IPO Date
- Jun 19, 2019
- CIK
- 0001623526
- Website
- stoketherapeutics.com
- Similar Companies
- Business
- Stoke Therapeutics, Inc. Stoke Therapeutics, Inc. (Nasdaq: STOK) is a clinical-stage biotechnology company that develops RNA-based medicines to treat severe genetic diseases caused by haploinsufficiencies, using its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform to upregulate protein expression from healthy genes via antisense oligonucleotides (ASOs). The company offers zorevunersen (STK-001), an investigational therapy in Phase 3 clinical trials for Dravet syndrome, a severe developmental epileptic encephalopathy; STK-002, in preclinical development for autosomal dominant optic atrophy (ADOA), the leading hereditary optic neuropathy; and additional pipeline programs targeting haploinsufficiency diseases of the central nervous system and eye. Founded in 2014 and headquartered in Bedford, Massachusetts, Stoke Therapeutics operates primarily in the United States with a focus on rare neurological disorders affecting pediatric and adult patients. Recent developments include the launch of the global Phase 3 EMPEROR study for zorevunersen in 2025, supportive long-term clinical data from prior trials, advancement of its second TANGO program into the clinic for ADOA, a $165 million upfront license and collaboration agreement with Biogen Inc. Biogen Inc. in early 2025 for zorevunersen commercialization rights outside North America with eligibility for up to $385 million in milestones and royalties, and a partnership with Acadia Pharmaceuticals Inc. Acadia Pharmaceuticals Inc. for novel RNA-based medicines in genetic neurodevelopmental diseases.
Company News
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Stoke Therapeutics, Inc. $STOK Shares Newly Acquired by Corient Private Wealth LP
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
Squarepoint Ops LLC Acquires Shares of 29,310 Stoke Therapeutics, Inc. $STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
Bank of America Corp DE Buys 336,931 Shares of Stoke Therapeutics, Inc. $STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics' Dravet Trial Tops Enrollment Target With Zero Dropouts
Dimensional Fund Advisors LP Buys 162,797 Shares of Stoke Therapeutics, Inc. $STOK
Stoke Therapeutics Q2 Earnings Call Highlights
These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results
Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates